Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Pei Huo is active.

Publication


Featured researches published by Pei Huo.


Bioorganic & Medicinal Chemistry Letters | 2010

Dihydro-pyrano[2,3-b]pyridines and tetrahydro-1,8-naphthyridines as CB1 receptor inverse agonists: Synthesis, SAR and biological evaluation

Christina B. Madsen-Duggan; John S. Debenham; Thomas F. Walsh; Lin Yan; Pei Huo; Junying Wang; Xinchun Tong; Julie Lao; Tung M. Fong; Jing Chen Xiao; Cathy R.-R.C. Huang; Chun-Pyn Shen; D. Sloan Stribling; Lauren P. Shearman; Alison M. Strack; Mark T. Goulet; Jeffrey J. Hale

Synthesis and structure-activity relationships of cannabinoid-1 receptor (CB1R) inverse agonists based on dihydro-pyrano[2,3-b] pyridine and tetrahydro-1,8-naphtyridine scaffolds are presented. Rat food intake and pharmacokinetic evaluation of 13g, 13i, 13k and 17a revealed these compounds to be highly efficacious orally active modulators of CB1R.


JCI insight | 2018

A glucose-responsive insulin therapy protects animals against hypoglycemia

Ruojing Yang; Margaret Wu; Songnian Lin; Ravi P. Nargund; Xinghai Li; Theresa M. Kelly; Lin Yan; Ge Dai; Ying Qian; Qing Dallas-Yang; Paul Fischer; Yan Cui; Xiaolan Shen; Pei Huo; Danqing Dennis Feng; Mark D. Erion; David E. Kelley; James Mu

Hypoglycemia is commonly associated with insulin therapy, limiting both its safety and efficacy. The concept of modifying insulin to render its glucose-responsive release from an injection depot (of an insulin complexed exogenously with a recombinant lectin) was proposed approximately 4 decades ago but has been challenging to achieve. Data presented here demonstrate that mannosylated insulin analogs can undergo an additional route of clearance as result of their interaction with endogenous mannose receptor (MR), and this can occur in a glucose-dependent fashion, with increased binding to MR at low glucose. Yet, these analogs retain capacity for binding to the insulin receptor (IR). When the blood glucose level is elevated, as in individuals with diabetes mellitus, MR binding diminishes due to glucose competition, leading to reduced MR-mediated clearance and increased partitioning for IR binding and consequent glucose lowering. These studies demonstrate that a glucose-dependent locus of insulin clearance and, hence, insulin action can be achieved by targeting MR and IR concurrently.


Diabetes | 2018

Erratum. Engineering Glucose Responsiveness Into Insulin. Diabetes 2018;67:299–308

Niels C. Kaarsholm; Songnian Lin; Lin Yan; Theresa M. Kelly; Margaret van Heek; James Mu; Margaret Wu; Ge Dai; Yan Cui; Yonghua Zhu; Ester Carballo-Jane; Vijay Bhasker G. Reddy; Peter Zafian; Pei Huo; Shuai Shi; Valentyn Antochshuk; Aimie M. Ogawa; Franklin Liu; Sandra C. Souza; Wolfgang Seghezzi; Joseph L. Duffy; Mark D. Erion; Ravi P. Nargund; David E. Kelley

In the above-mentioned article, several scientists were erroneously omitted from the acknowledgments section. The authors wish to acknowledge Hsuan-shen Chen, Huaibing He, Tina …


Archive | 2004

(3,4-disubstituted)propanoic carboxylates as s1p (edg) receptor agonists

Vincent J. Colandrea; George Doherty; Jeffrey J. Hale; Pei Huo; Irene E. Legiec; Leslie Toth; Petr Vachal; Lin Yan


Bioorganic & Medicinal Chemistry Letters | 2006

Discovery of 3-arylpropionic acids as potent agonists of sphingosine-1-phosphate receptor-1 (S1P1) with high selectivity against all other known S1P receptor subtypes.

Lin Yan; Pei Huo; George Doherty; Lesile Toth; Jeffrey J. Hale; Sander G. Mills; Richard Hajdu; Carol Ann Keohane; Mark Rosenbach; James A. Milligan; Gan-Ju Shei; Gary Chrebet; James D. Bergstrom; Deborah Card; Elizabeth J. Quackenbush; Alexandra Wickham; Suzanne M. Mandala


Bioorganic & Medicinal Chemistry Letters | 2007

SAR studies of 3-arylpropionic acids as potent and selective agonists of sphingosine-1-phosphate receptor-1 (S1P1) with enhanced pharmacokinetic properties.

Lin Yan; Pei Huo; Jeffrey J. Hale; Sander G. Mills; Richard Hajdu; Carol Ann Keohane; Mark Rosenbach; James A. Milligan; Gan-Ju Shei; Gary Chrebet; James D. Bergstrom; Deborah Card; Suzanne M. Mandala


Archive | 2008

Substituted pyrano [2, 3 - b] pyridine derivatives as cannabinoid -1 receptor modulators

John S. Debenham; Jeffrey J. Hale; Pei Huo; Christina B. Madsen-Duggan; Thomas F. Walsh; Lin Yan


Bioorganic & Medicinal Chemistry Letters | 2006

2-Aryl(pyrrolidin-4-yl)acetic acids are potent agonists of sphingosine-1-phosphate (S1P) receptors.

Lin Yan; Richard J. Budhu; Pei Huo; Christopher L. Lynch; Jeffrey J. Hale; Sander G. Mills; Richard Hajdu; Carol Ann Keohane; Mark Rosenbach; James A. Milligan; Gan-Ju Shei; Gary Chrebet; James D. Bergstrom; Deborah Card; Suzanne M. Mandala


Bioorganic & Medicinal Chemistry Letters | 2006

2,5-Disubstituted pyrrolidine carboxylates as potent, orally active sphingosine-1-phosphate (S1P) receptor agonists

Vincent J. Colandrea; Irene E. Legiec; Pei Huo; Lin Yan; Jeffrey J. Hale; Sander G. Mills; James D. Bergstrom; Deborah Card; Gary Chebret; Richard Hajdu; Carol Ann Keohane; James A. Milligan; Mark Rosenbach; Gan-Ju Shei; Suzanne M. Mandala


Archive | 2016

Insulin receptor partial agonists

Songnian Lin; Lin Yan; Pei Huo; Dmitri Pissarnitski; Danqing Feng; Ravi P. Nargund; Yuping Zhu; Ahmet Kekec; Christina B. Madsen-Duggan; Zhi-cai Shi; Zhicai Wu; Yingjun Mu

Researchain Logo
Decentralizing Knowledge